1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2017

Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2017

  • February 2017
  • -
  • Global Markets Direct
  • -
  • 67 pages

Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Onychomycosis (Tinea Unguium) – Pipeline Review, H1 2017, provides an overview of the Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline landscape.

Onychomycosis is a chronic fungal infection of the nails caused by dermatophytes. Symptoms include thickened nail that is difficult to cut, brittle or ragged nail, discolored or unsightly nail and pain of the finger or toe with ordinary activities. Treatment includes antifungal medications and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Onychomycosis (Tinea Unguium) – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical, Discovery and Unknown stages are 4, 6, 3, 3 and 1 respectively.

Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2017
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Onychomycosis (Tinea Unguium) - Overview
Onychomycosis (Tinea Unguium) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Onychomycosis (Tinea Unguium) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development
Almirall SA
Arno Therapeutics Inc
Blueberry Therapeutics Ltd
Dermala Inc
Eisai Co Ltd
Helix BioMedix Inc
Hexima Ltd
Meiji Seika Pharma Co Ltd
Moberg Pharma AB
NAL Pharmaceuticals Ltd
Nihon Nohyaku Co Ltd
Novabiotics Ltd
Novan Inc
Viamet Pharmaceuticals Inc
Onychomycosis (Tinea Unguium) - Drug Profiles
AR-12 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
BB-0305 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
BB-2603 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Drug for Onychomycosis - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
ELS-160 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
fosravuconazole - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
HB-1275 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
HXP-124 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
luliconazole - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
ME-1111 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
NAL-3210 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
NP-213 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
P-3058 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
SB-208 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
terbinafine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
terbinafine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
VT-1161 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Onychomycosis (Tinea Unguium) - Dormant Projects
Onychomycosis (Tinea Unguium) - Discontinued Products
Onychomycosis (Tinea Unguium) - Product Development Milestones
Featured News and Press Releases
Sep 28, 2016: Moberg Pharma Begins Patient Enrollment in North America and Europe in Two Phase 3 Studies of MOB-015 in Onychomycosis
Aug 10, 2016: Moberg Pharma Announces Approvals to Start Phase 3 Study For MOB-015 In U.S. And Canada
Jul 21, 2016: Novan Announces First Patient Dosed in Phase 2 Anti-Fungal Program
Jul 13, 2016: Viamet to Present Interim RENOVATE Results at the American Podiatric Medical Association 2016 Annual Meeting
Jul 05, 2016: Moberg Pharma announces submission of applications to start Phase 3 studies for MOB-015
May 18, 2016: Moberg Pharma Announces Multiple Patent Approvals for MOB-015
Mar 02, 2016: Viamet Reports Positive Results from Interim Analysis of RENOVATE Phase 2b Trial of VT-1161 in Onychomycosis
Jan 21, 2016: Moberg Pharma is contemplating a potential bond issue, updates financial targets and provides update on MOB-015
Jan 07, 2016: Viamet to Present at the 3rd Annual Dermatology Summit
Jul 15, 2015: Viamet to Present at American Podiatric Medical Association 2015 Annual Scientific Meeting
Mar 26, 2015: Moberg Pharma Announces Grant of EU Patent for MOB-015 Related to Topical Treatment of Onychomycosis (Nail Fungus)
Mar 13, 2015: MOB-015 Data To Be Presented At The 73rd Annual Meeting Of The American Academy Of Dermatology
Mar 10, 2015: Viamet Announces Initiation of RENOVATE Phase 2b Study of Oral VT-1161 in Onychomycosis
Feb 11, 2015: Moberg Pharma Announces Issue of U.S. Patent Related to MOB-015 for the Treatment of Onychomycosis
Sep 17, 2014: Moberg Pharma Announces Successful Results for MOB-015 in a Phase II Study for the Treatment of Onychomycosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Onychomycosis (Tinea Unguium), H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Onychomycosis (Tinea Unguium) - Pipeline by Almirall SA, H1 2017
Onychomycosis (Tinea Unguium) - Pipeline by Arno Therapeutics Inc, H1 2017
Onychomycosis (Tinea Unguium) - Pipeline by Blueberry Therapeutics Ltd, H1 2017
Onychomycosis (Tinea Unguium) - Pipeline by Dermala Inc, H1 2017
Onychomycosis (Tinea Unguium) - Pipeline by Eisai Co Ltd, H1 2017
Onychomycosis (Tinea Unguium) - Pipeline by Helix BioMedix Inc, H1 2017
Onychomycosis (Tinea Unguium) - Pipeline by Hexima Ltd, H1 2017
Onychomycosis (Tinea Unguium) - Pipeline by Meiji Seika Pharma Co Ltd, H1 2017
Onychomycosis (Tinea Unguium) - Pipeline by Moberg Pharma AB, H1 2017
Onychomycosis (Tinea Unguium) - Pipeline by NAL Pharmaceuticals Ltd, H1 2017
Onychomycosis (Tinea Unguium) - Pipeline by Nihon Nohyaku Co Ltd, H1 2017
Onychomycosis (Tinea Unguium) - Pipeline by Novabiotics Ltd, H1 2017
Onychomycosis (Tinea Unguium) - Pipeline by Novan Inc, H1 2017
Onychomycosis (Tinea Unguium) - Pipeline by Viamet Pharmaceuticals Inc, H1 2017
Onychomycosis (Tinea Unguium) - Dormant Projects, H1 2017
Onychomycosis (Tinea Unguium) - Dormant Projects, H1 2017 (Contd..1), H1 2017
Onychomycosis (Tinea Unguium) - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Onychomycosis (Tinea Unguium), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016’, provides in depth ...

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2016

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline ...

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Pipeline Review, H2 2016

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Pipeline Review, H2 ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.